STYLE SHEET
GLOBAL CSS
COLORS
ANIMATIONS
MEDIA QUERY
SPACING SYSTEM

Why only for healthcare professionals?

The content on these information pages is directed solely at you if you are a doctor, nurse, or pharmacist, as it concerns treatment with prescription medicines.

Please confirm that you are a healthcare professional (healthcare assistant, nurse, doctor, psychologist, or other licensed healthcare professional).

Back to main page

Confirm and continue

News
April 11, 2024

Yazen transforms the accessibility of obesity treatment

Yazen tackles the challenge with groundbreaking, accessible, and comprehensive treatment approach

Since the World Health Organization recognized obesity as a chronic disease back in 1997, it has only recently begun to be treated as such. Yazen, a Swedish healthcare service, tackles this challenge with a groundbreaking, accessible, and comprehensive treatment approach.

By focusing on the hormonal imbalance that causes obesity, Yazen offers medical treatments that work in conjunction with lifestyle changes, guided by a team of health experts. With their new treatment philosophy and an innovative digital platform, Yazen paves the way for more preventive care and hope for a healthier future for patients across Sweden – and soon, the world over.

Read full article on Näringsliv.se (page 7)

More news

WOD26: Data Reveals Persistent Shame & Stigma Around Obesity Treatment

Ahead of World Obesity Day on 4 March, Yazen is sharing new findings from internal patient data, revealing that shame and stigma remain major barriers to obesity care — even as effective medical treatments become more widely available.

UK firms eye GLP-1 benefits to cut sick leave and boost performance.

UK employers are increasingly considering weight-loss support as part of employee benefits, as new Yazen patient data links GLP-1 treatment to reduced sick days and improved workplace performance.

Yazen achieved record-breaking growth in 2025, doubling its revenue.

In 2025, Yazen's revenue surged 87% to nearly €29.4 million, with gross profits doubling to €16.5 million. Now treating over 37,000 active patients across seven countries, the company is eyeing further expansion into two more markets in 2026. Despite an EBITDA of –€5.7 million due to heavy growth investment, Yazen remains a leader in European obesity care.